JNJ-67856633

Research use only, not for human use.

JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. JNJ-67856633 in some cases lead to tumor stasis.

JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. JNJ-67856633 in some cases lead to tumor stasis.(In Vitro):JNJ-67856633 is effective and highly bioavailable in both mouse and rat tumors, and in some cases led to tumor stasis. JNJ-67856633 leads to potent in vivo pharmacodynamic shutdown in CD79b- as well as CARD11-mutant ABC-DLBCL models as measured by serum IL10 or uncleaved BCL10 levels in tumors.(In Vivo):Dose dependent inhibition of the generation of Tregs (CD4+CD25+FoxP3+) following CD3/28 stimulation was observed upon treatment with JNJ-67856633 suggesting a potential immune modulatory role of MALT1 inhibition.

——

——

——

NF-κB

MALT1

c-Myc-MAX|PARP|Apoptosis

——

——

2230273-76-2

467.32

C20H11F6N5O2

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (267.48 mM)

N/A

——

(-20℃)

With Ice Pack

≥ 2 years